Fractyl Health Inc., a metabolic therapeutics company, has announced advancements in its Rejuva Smart GLP-1 pancreatic gene therapy platform, specifically with its clinical candidate RJVA-001 targeting type 2 diabetes (T2D). The company revealed new preclinical data at the American Diabetes Association's 85th Scientific Sessions, demonstrating that a single dose of Rejuva was well-tolerated in healthy mice and effectively prevented obesity and diabetes in models exposed to a high-fat diet. These findings support the progression of RJVA-001 toward first-in-human studies, with preliminary clinical data expected in 2026, pending regulatory authorization. The study results have already been presented.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。